When you’re looking into treatments for Multiple Sclerosis, it helps to know that not all therapies aim to do the same thing.

Two you might come across are NCT and aHSCT. Here’s a simple breakdown of what each one does, what it can’t do, the risks involved, and who’s actually a good candidate.

In short

The primary difference between these two treatments lies in their therapeutic objectives:

• aHSCT focuses on deep immune suppression to stop active autoimmune attacks.

• NCT focuses on regenerative stability—aiming to repair and protect the nervous system.

Here is a clear breakdown of their objectives, limitations, risks, and who actually qualifies for them.

The Approach to Autoimmunity: Suppression vs. Modulation

Addressing autoimmunity is the only area where these two treatments share a common goal, but they go about it in vastly different ways.

Understand aHSCT (The Chemotherapy Approach)

aHSCT stands for Autologous Hematopoietic Stem Cell Transplant. Despite the name, it is important to understand that this is classic chemotherapy, a treatment conventionally used for blood cancers.

• How it works: Chemotherapy uses harsh chemicals to eliminate your circulating blood components. Afterward, your own bone marrow is reintroduced to “rescue” and regenerate your blood supply.

• The “Stem Cell” Misconception: Many patients mistakenly believe the “stem cell” part of this treatment will regenerate nerve damage caused by MS. In reality, the stem cells (bone marrow) are only used to help you survive the destructive effects of the chemotherapy. aHSCT does not address or repair the degenerative changes associated with MS.

• The Limitations: Recent science shows that MS degeneration is largely driven by B lymphocytes (B cells), which are governed by your adaptive immune system. While wiping out your blood provides temporary relief, aHSCT does not permanently reset your adaptive immune system. Therefore, it only offers a temporary halt to autoimmune degeneration, rather than a permanent fix for B cell behavior.

• The Risks: Because it eliminates your immune system, it leaves a dangerous “immune gap.” Patients require critical life support and specialized nutrition while their blood regenerates, making this a high-risk procedure.

Who Actually Qualifies for aHSCT?

Not every MS patient has active B-cell autoimmunity. While early tests (like ANA/ENA) might show active autoimmunity when symptoms first appear, tests done 2 or more years later often show that the active autoimmune phase has passed.

• If your autoimmunity is not active: You may still experience temporary symptom flare-ups triggered by minor infections or allergies, but aHSCT will not help you. Because aHSCT does not alter the underlying “programming” of your immune system, patients experiencing direct neurodegenerative symptoms without active autoimmunity will not respond to the treatment.

• The Screening Problem: Only patients with active autoimmune damage (easily detected through ANA tests) naturally benefit from immune suppression. Unfortunately, because aHSCT is an off-label treatment for MS and is heavily promoted in medical tourism destinations (like Mexico), basic qualifying tests are often skipped. This regulatory lapse exposes many patients to the severe, long-term risks of unnecessary chemotherapy.

Understanding NCT (The Regenerative Approach)

In contrast to the destructive nature of chemotherapy, the NCT protocol directly targets the underlying pathology of MS.

How it works: NCT utilizes specialized cells (differentiated multipotent cellular lineages) and concentrated growth factors. These are administered directly into specific spaces surrounding the brain and spine (the supratentorial and thecal spaces). All interventions are minimally invasive.

The Clinical Pillars

Instead of simply suppressing the immune system, NCT is built on five pillars of healing:

• Cytokine Immune Modulation: Balancing the immune system.

• Cerebrovascular Regeneration: Repairing the blood vessels in the brain.

• Angiogenesis: Forming new, healthy blood vessels.

• Neurogenesis: Growing new nerve tissue.

• Neuroplasticity: Helping the brain form new neural connections.

Targeting the Damage: NCT addresses the specific breakdown of cells (endothelial and oligodendrocyte degeneration) that causes brain lesions and demyelination, aiming to produce long-term results.

Advanced Support: A third procedure within the protocol specifically tackles nerve pain (radiculopathy) caused by spinal stenosis in patients with higher EDSS (Expanded Disability Status Scale) scores.

A Focus on Long-Term Disease Control

When compared side-by-side, NCT stands at the forefront of disease control for the broader MS population.

NCT is designed as a one-time solution with realistically predictable outcomes, evaluated at the time of your inclusion screening. In specific cases, it can even reverse symptoms without side effects.

aHSCT, by contrast, is a reactive, ongoing requirement with low predictability and significant risks.

Compared	aHSCT	NCT
Approach	Immunosuppressioin	Repairs the nervous system
Nature	Ongoing/reactive, high risk	One-time, low risk
Who it may help	Patients with ANA Positive	ANA +/- , EDSS 1~4.5 (ideal), EDSS 5~8.5
Who it may not help	Patients with ANA Negative	Patients on CNS prescriptions